| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 1.0 | 0.0 |
| Profit before tax | -1.6 | -0.6 |
| Net income | -1.7 | 0.0 |
| EPS (diluted, $ a share) | $-0.28 | $0.01 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Operating margin | -169.1% |
|---|
10-Q filed with the SEC, NASDAQ: KPRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kiora Pharmaceuticals Inc: key numbers
- Share price
- $0.9300Close, Nov 17
- Market cap
- $4.11M
- Shares outstanding
- 4.42MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kiora Pharmaceuticals Inc
All →Kiora Pharmaceuticals Financial Results
Kiora Pharmaceuticals reported third quarter 2026 financial results and highlighted the strategic in-licensing of KIO-401, a late-stage oral neuroprotective asset for retinal diseases. The company ended the quarter with $16.3 million in cash and is preparing for a Phase 3 registration trial for KIO-401 in patients with Central Retinal Artery Occlusion (CRAO).
“The addition of KIO-401 transforms Kiora into a late-stage retinal therapeutics company. We are building on the significant amount of CMC, non-clinical and clinical data that already exists on KIO-401 through Senju’s previous and ongoing efforts. With exclusive rights outside Asia, we are preparing for a single, phase 3, registration trial of KIO-401 in patients across the United States, Europe and other territories.”
Brian M. Strem, Ph.D., President and Chief Executive Officer
Kiora Pharmaceuticals Licensing Deal with Senju Pharmaceutical Co., Ltd. Worth $3.5M
Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical to develop and commercialize KIO-401, a late-stage oral small-molecule calpain inhibitor for ophthalmic diseases, in all territories outside of Asia. Kiora will pay an upfront fee of $3.5 million, low teen millions upon technology transfer, and up to $168.5 million in potential regulatory and commercial milestones, plus single-digit royalties.
- Value
- $3.5M
- Counterparty
- Senju Pharmaceutical Co., Ltd.